AtriCure, Inc. (ATRC) EPS Estimated At $-0.26

April 19, 2018 - By Clifton Ray

AtriCure, Inc. (NASDAQ:ATRC) LogoInvestors sentiment decreased to 1.13 in 2017 Q4. Its down 0.90, from 2.03 in 2017Q3. It is negative, as 17 investors sold AtriCure, Inc. shares while 31 reduced holdings. 19 funds opened positions while 35 raised stakes. 26.90 million shares or 0.49% more from 26.77 million shares in 2017Q3 were reported.
Parallax Volatility Advisers L P owns 4,956 shares. Emerald Mutual Fund Advisers Trust owns 489,106 shares for 0.35% of their portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) holds 2,044 shares or 0% of its portfolio. Vanguard Group Inc has invested 0% in AtriCure, Inc. (NASDAQ:ATRC). New York State Common Retirement Fund accumulated 33,100 shares. Tudor Investment Corporation Et Al owns 0.01% invested in AtriCure, Inc. (NASDAQ:ATRC) for 23,678 shares. State Street Corporation holds 673,029 shares or 0% of its portfolio. Laurion Management Ltd Partnership holds 0% or 51,831 shares in its portfolio. Prelude Cap Management Limited Liability stated it has 19,052 shares or 0.03% of all its holdings. Teacher Retirement Of Texas holds 0% or 11,140 shares. Schwab Charles Inv Mngmt Incorporated owns 173,033 shares for 0% of their portfolio. Aqr Cap Mgmt Ltd has invested 0% in AtriCure, Inc. (NASDAQ:ATRC). Alphamark Advsrs Ltd Liability stated it has 0% in AtriCure, Inc. (NASDAQ:ATRC). New York-based First Manhattan has invested 0% in AtriCure, Inc. (NASDAQ:ATRC). Nuveen Asset Mngmt Ltd Liability Co holds 0.01% of its portfolio in AtriCure, Inc. (NASDAQ:ATRC) for 60,981 shares.

Since February 15, 2018, it had 2 insider buys, and 2 sales for $56,650 activity. The insider Drake Scott William bought 11,000 shares worth $194,040. Krell Elizabeth D sold $200,000 worth of AtriCure, Inc. (NASDAQ:ATRC) on Monday, March 12. Noznesky Justin J had sold 4,000 shares worth $68,120.

Analysts expect AtriCure, Inc. (NASDAQ:ATRC) to report $-0.26 EPS on April, 26 after the close.They anticipate $0.06 EPS change or 18.75 % from last quarter’s $-0.32 EPS. After having $-0.08 EPS previously, AtriCure, Inc.’s analysts see 225.00 % EPS growth. It closed at $21.53 lastly. It is down 5.35% since April 19, 2017 and is uptrending. It has underperformed by 6.20% the S&P500.

AtriCure, Inc. (NASDAQ:ATRC) Ratings Coverage

Among 4 analysts covering Atricure (NASDAQ:ATRC), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Atricure had 8 analyst reports since November 2, 2017 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, February 27 by Canaccord Genuity. Canaccord Genuity maintained AtriCure, Inc. (NASDAQ:ATRC) rating on Monday, January 8. Canaccord Genuity has “Buy” rating and $24.0 target. As per Tuesday, January 16, the company rating was maintained by Needham. The rating was maintained by Piper Jaffray with “Buy” on Sunday, December 10. Canaccord Genuity maintained AtriCure, Inc. (NASDAQ:ATRC) on Thursday, November 2 with “Buy” rating. The rating was maintained by Needham with “Buy” on Thursday, November 2. The firm has “Buy” rating by Needham given on Tuesday, February 27.

AtriCure, Inc. provides atrial fibrillation solutions to medical centers in the United States and internationally. The company has market cap of $755.20 million. The firm offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures, such as coronary artery bypass grafting and/or valve replacement or repair; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery. It currently has negative earnings. It also provides SUBTLE cannula, an access device and conduit for the ablation device and endoscope to enable a closed chest endoscopic approach; multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable physicians to create an expanded cardiac ablation lesion set.

AtriCure, Inc. (NASDAQ:ATRC) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: